ARS Pharmaceuticals, Inc. SPRY Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by ARS Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The official record: ARS Pharmaceuticals, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about ARS Pharmaceuticals, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ARS Pharmaceuticals, Inc.'s cash & equivalents?
- ARS Pharmaceuticals, Inc. (SPRY) reported cash & equivalents of $24.32M in Q1 2026.
- How has ARS Pharmaceuticals, Inc.'s cash & equivalents changed year-over-year?
- ARS Pharmaceuticals, Inc.'s cash & equivalents decreased by 39.0% year-over-year, from $39.86M to $24.32M.
- What is the long-term trend for ARS Pharmaceuticals, Inc.'s cash & equivalents?
- Over 5 years (2020 to 2025), ARS Pharmaceuticals, Inc.'s cash & equivalents has grown at a -36.1% compound annual growth rate (CAGR), from $386.92M to $41.32M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.